Eric Schmidt
Low Vision Rehabilitation · Elizabethtown, NCNPI 1922007368
Payments from drug & device makers
Across 537 payments — averaging $540.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$186K
- Bausch & Lomb Americas Inc.$41K
- Topcon Healthcare, Inc.$13K
- Harrow Eye, LLC$10K
- Aerie Pharmaceuticals, Inc.$6K
- Alcon$5K
- plus $29K from 28 others
What the payments were for
- Consulting fees$82,41528%
- Speaking & faculty fees$161,45756%
- Travel & lodging$31,17911%
- Food & beverage$15,2145%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 292 | $185,911 |
| Bausch & Lomb Americas Inc. | 67 | $41,147 |
| Topcon Healthcare, Inc. | 12 | $12,612 |
| Harrow Eye, LLC | 19 | $10,156 |
| Aerie Pharmaceuticals, Inc. | 16 | $6,004 |
| Alcon | 22 | $5,034 |
| Thea Pharma Inc. | 10 | $4,494 |
| Tarsus Pharmaceuticals, Inc. | 8 | $4,308 |
| Shire North American Group Inc | 4 | $2,703 |
| Glaukos Corporation | 6 | $2,540 |
| Heru, Inc. | 2 | $2,500 |
| Biotissue Holdings Inc. | 14 | $2,251 |
| Carl Zeiss Meditec, Inc. | 8 | $1,835 |
| Kala Pharmaceuticals, Inc. | 10 | $1,651 |
| Ocular Therapeutix, Inc. | 4 | $1,380 |
| Tearlab Corp | 2 | $1,356 |
| Lumenis BE Inc | 1 | $1,200 |
| Apellis Pharmaceuticals, Inc. | 1 | $786 |
| Ivantis, Inc | 1 | $675 |
| Topcon Corporation | 1 | $238 |
| Sight Sciences, Inc. | 6 | $225 |
| Novartis | 2 | $195 |
| LKC Technologies, Inc. | 3 | $176 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $174 |
| Sun Pharmaceutical Industries Inc. | 5 | $168 |
| Oyster Point Pharma, Inc. | 5 | $133 |
| Coopervision Inc. | 2 | $132 |
| Johnson & Johnson Vision Care, Inc. | 4 | $89 |
| Carl Zeiss Meditec USA, Inc. | 2 | $68 |
| Topcon Healthcare Solutions, Inc. | 1 | $52 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Notal Vision, Inc. | 1 | $26 |
| Dompe US, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$70,439
- VUITY$42,887
- COMBIGAN$42,242
- XIIDRA$39,373
- MIEBO$37,345
- RESTASIS MULTIDOSE$18,256
- RESTASIS$16,027
- ALPHAGAN P$12,053
- VEVYE$8,001
- Rhopressa$7,462
- Rocklatan$6,390
- XDEMVY$3,260
- Heru HMD$2,500
- DURYSTA$2,475
- IYUZEH$2,250
- EYSUVIS$1,500
- DEXTENZA$1,360
- TearLab Osmolarity System$1,356
- optilight$1,200
- Travoprost Intraocular Implant - iDose$1,155
How this compares
Too few low vision rehabilitation providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 52 | $62,009 |
| LumiganBimatoprost | 64 | $25,886 |
| XiidraLifitegrast | 19 | $18,755 |
| MieboPerfluorohexyloctane/Pf | 20 | $14,527 |
| VyzultaLatanoprostene Bunod | 25 | $10,318 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $9,427 |
| Alphagan PBrimonidine Tartrate | 23 | $6,056 |
| RhopressaNetarsudil Mesylate | 14 | $5,561 |
| Lotemax SmLoteprednol Etabonate | 13 | $5,056 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 25 | $3,182 |
| Brimonidine Tartrate | 22 | $2,746 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,904 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 26 | $1,882 |
| Travoprost | 16 | $1,546 |
| Loteprednol Etabonate | 11 | $1,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $185,911 | $103,378165 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $41,147 | $43,60064 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $174 | $6,40824 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $6,004 | $5,56114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few low vision rehabilitation providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other low vision rehabilitation in Elizabethtown
- Elana ScheinerApex$906
- Alexandra RobertsonCharlotte$787
- Madison DunningDurham$488
- Elven SmithRockingham$208
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.